Despite improvements in modern medical therapies, inflammatory diseases, such as
atherosclerosis, diabetes, non-alcoholic fatty liver, chronic kidney diseases, and …

As the most abundant internal mRNA modification in eukaryotic cells, N 6-methyladenosine
(m6A) has emerged as an important regulator of gene expression and has a profound …

Abstract N 6-methyladenosine (m 6 A) is the most common internal modification of mRNAs
in higher eukaryotic. This process is performed by methyltransferase. Methyltransferase-like …

Methyltransferase‐like 3 (METTL3), an RNA N6‐methyladenosine (m6A) methyltransferase,
is essential for the m6A mRNA modification. As a key enzyme of m6A methylation …

Abstract N 6-methyladenosine (m 6 A) is a prevalent mRNA modification that plays a crucial
function in multiple biological processes. Methyltransferase-like 3 (METTL3), an m 6 A …

Atherosclerosis, characterized as the chronic inflammation of the arterial wall, is one of the
leading causes of coronary artery disease (CAD), and macrophages are found to play …

Background Systemic lupus erythematosus (SLE) is an autoimmune disorder in which
excessive CD4+ T-cell activation and imbalanced effector T-cell differentiation play critical …

Gastrointestinal cancer is the most common human malignancy characterized by high
lethality and poor prognosis. Emerging evidences indicate that N6-methyladenosine (m6A) …

Abstract RNA N6-methyladenosine (m 6 A) modification is abundant in eukaryotes, bacteria
and archaea. It is an RNA modification mainly existing in messenger RNA (mRNAs) and has …

Abstract N 6-methyladenosine (m 6 A) is the most abundant mRNA modification and is
catalyzed by the methyltransferase complex, in which methyltransferase-like 3 (METTL3) is …